PM-Scl 100/75 positive patients presented mostly a pulmonary fibrotic pattern (p <0.05) and, also, heart complications were more likely associated with anti PM-Scl 100/75 positivity (p <0.05). The risk prediction model for organ-specific complications had an accuracy of 84.4% (95%CI 78, 89) in complication-site prediction, AUC of 0.871, 86% of The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar.
I recently did all my blood work and a mysotis III panel (labcorp) came back with slightly abnormal RNP (25.2) and PM-SCL 100 being Positive Abnormal. All my other blood work came back normal or negative (including Myositis II panel which doesn't include tests for RNP and PM-SCL and negative ANA) except for the CK levels being around 500 Anticorpii anti PM-Scl sunt îndreptați împotriva proteinelor complexului nucleolar PM-Scl, compus din 11-16 polipeptide în care componentele antigenice au greutăți moleculare cuprinse între 20 kDa și 110 kDa. Principalele antigene sunt 2 polipeptide de 75 și respectiv 100 kDa, cunoscute ca PM-Scl 75 și PM-Scl 100. Cele 2 antigene sunt.
PM-Scl (PM1) Antibody, IgG. Plasma. Contaminated, hemolyzed, or severely lipemic specimens. 1-4 days upon receipt at reference laboratory. The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc. The antibodies are usually associated with positive ANA with nucleolar patterns. Anti-PM-Scl may be directed to different subunits in the PM-Scl complex, usually the 75 kD and 100 kD subunits. Anti-PM-Scl is often associated with Raynaud's phenomenon, arthritis, muscle aches and effects on the skin and lungs FAPMA : The anti-PM/Scl-100 antibody is associated with younger age, calcinosis and has lower rates of gastrointestinal symptoms, ILD and pulmonary hypertension. There is also evidence of a possibly better survival compared to the presence of either anti-PM/Scl-75 or anti-Scl-70 antibodies Although the sera of more patients with PM/scleroderma, scleroderma, PM, or DM have to be analyzed with the full-length PM-Scl-75 antigen, our data strongly suggest that, if only PM-Scl-100 is used in ELISAs, a significant number of patients will have negative test results because anti-PM-Scl-75 antibodies remain undetected
Anti-PM/Scl-100 Ab - The anti-PM/Scl-100 antibody is associated with younger age, calcinosis and has lower rates of gastrointestinal symptoms, ILD and pulmonary hypertension. There is also evidence of a possibly better survival compared to the presence of either anti-PM/Scl-75 or anti-Scl-70 antibodies SDS-PAGE (purity> 70%); Western blot with i: anti PM/Sci 100 autoantibody-positive sample; ii: monoclonal anti-His-tag antibody. Calculated Molecular Weight 102 kDa Calculated Isoelectric Point pH 8.7 Coating Concentration 0.4-0.8 µg/ml (depending on the type of ELISA plate and coating buffer). Suitable for labeling of functional groups There was a significant association between positivity for anti-PM/Scl 100 alone and malignancy (p=0.037) when compared to presence of both reactivities or reactivity to PM/Scl75 alone. 13 patients (18.6%) had developed a malignancy, 4 of these had onset within 36 months from SSc diagnosis and all were positive for anti-PM/Scl 100, combined. Anti-PM/Scl-100 Ab (RDL) A 34 High Units <20 01 Anti-Ku Ab (RDL) A Strong Positive Abnormal Negative 01 Anti-SS-A 52kD Ab, IgG (RDL) A 44 High Units <20 01 Anti-U1 RNP Ab (RDL) A 34 High Units <20 01 Anti-U2 RNP Ab (RDL) A Weak Positive Abnormal Negative 01 Anti-U3 RNP (Fibrillarin)(RDL) A Moderate Positive Abnormal Negative 0
PM-Scl 100-kd protein was isolated and sequenced, with a predicted protein of 860 amino acids and molecular mass of 98.87 kd (7). A second cDNA encoding the PM-Scl 100-kd protein derived from HeLa cells has also been described, with a predicted protein of 885 aa, that was identical to the thymocyte form except for a 75-b The anti-PM/Scl-100 antibody is associated with younger age, calcinosis and has lower rates of gastrointestinal symptoms, ILD and pulmonary hypertension. There is also evidence of a possibly better survival compared to the presence of either anti-PM/Scl-75 or anti-Scl-70 antibodies If you are ANA negative by IF with a low positive Scl-70, it is almost always a false positive. However, there is one exception. If the lab uses a 1:80 cutoff for the ANA/IFA test, you could have a titer of 1:40 and in that case it is possible that the Scl-70 is very low because you are very early in the disease process. That is unlikely, however Scleroderma Antibodies and Clinical Relevance. Historically, systemic scleroderma was diagnosed as either diffuse or limited. The presence of anti-SCL-70 (anti-topoisomerase) antibodies is highly specific to the diagnosis of diffuse scleroderma, while the presence of anti-centromere antibodies is highly specific to the diagnosis of limited.
Anti-PM/Scl is associated with lung problems and an overlap of polymyositis and scleroderma. Children with PM-scleroderma overlap tend to have a strongly positive antinuclear antibody (ANA). HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is a key enzyme in the production of cholesterol Results Forty-one anti-PM/Scl-positive, 132 AS, 178 DM, and 135 IMNM patients were included. Although muscle weakness was a presenting feature in just 37% of anti-PM/Scl-positive patients, 93% eventually developed weakness. Unlike the other groups, anti-PM-Scl-positive patients had more severe weakness in arm abductors than hip flexors Mitogen's Scleroderma / Systemic Sclerosis Profile is a comprehensive autoimmune diagnostic test for scleroderma-specific autoantibodies directed against CENP, Scl-70/topo I, RNA polymerase, U3-RNP (fibrillarin), Th/To and other scleroderma-related autoantibodies. Each autoantibody (and combinations of autoantibodies) has been associated with. tion of anti-PM/Scl antibody-positive patients develop PM only (10-15), and determining the clinical features in those cases can be difficult. Another study of 41 anti-PM/Scl-positive patients stated that muscle weakness was present in 37% initially but was ultimately confirmed in 93% of pa-tients during follow-up (mean follow-up, 6.5±4.7.
The anti-PM-Scl antibodies can be further subdivided into two major subgroups, the anti-PM-Scl-75  and the anti-PM-Scl-100 . Anti-PM-Scl-75 antibodies are more common in patients with dcSSc and are associated with a higher prevalence of lung involvement, joint contractures and muscular atrophy than anti-PM-Scl-75 negative patients Background Anti-PM/Scl (a-PM/Scl) antibodies are found in different systemic autoimmune disease such as polymyositis, dermatomyositis, systemic sclerosis (SSc), and overlap syndromes. According to literature they are detected in about 2% of patients with SSc, but their presence are more common in SSc with myositis overlap. Features positively associated with the presence of a-PM/Scl antibodies. Forty-one anti-PM/Scl-positive, 132 AS, 178 DM, and 135 IMNM patients were included. Although muscle weakness was a presenting feature in just 37% of anti-PM/Scl-positive patients, 93% eventually developed weakness. Unlike the other groups, anti-PM-Scl-positive patients had more severe weakness in arm abductors than hip flexors PM-Scl 100/75 positive patients presented mostly a pulmonary fibrotic pattern (p <0.05) and, also, heart complications were more likely associated with anti PM-Scl 100/75 positivity (p <0.05). The. SCL70 : Scl 70 (topoisomerase 1) is a 100-kD nuclear and nucleolar enzyme. Scl 70 antibodies are considered to be specific for scleroderma (systemic sclerosis) and are found in up to 60% of patients with this connective tissue disease. Scl 70 antibodies are more common in patients with extensive cutaneous involvement and interstitial pulmonary fibrosis, and are considered a poor prognostic.
Another pattern, known as a nucleolar pattern, is common in people with scleroderma. The anti-double-stranded DNA antibody (anti-dsDNA) is a specific type of ANA antibody found in about 30% of people with systemic lupus. Less than 1% of healthy individuals have this antibody, making it helpful in confirming a diagnosis of systemic lupus All 4 cases were positive for anti-PM/Scl and eventually developed symptoms consistent with overlap SSc/myositis. Patient 1 was an 8-year-old white male who presented with diffuse hand swelling, tight skin, and contractures of the metacarpophalangeal (MCP) Extractable nuclear antigens (ENAs) include more than 100 different soluble cytoplasmic and nuclear antigens. The most commonly used ENA tests include tests for Smith, Sm/RNP (or U1 RNP), SSA-52 (Ro52), SSA-60 (Ro60), SSB, Scl-70 (topoisomerase 1), and Jo-1 antibodies. These are usually the first-line tests after a positive ANA result I am a forty year old women normally in good health. I received a positive result on two separate ANA tests (1:2560, homogeneous), which is apparently quite high. Subtest scores were all negative except Anti-scl-70 (2.0), anti-SM (1.1). I went to the doctor for the following symptoms: fatigue, anxiety, nausea, cold flashes. These symptoms came on all of a sudden and have persisted for three.
Originally, most PM/Scl-positive sera have been shown to contain anti-PM/Scl-100 and about 50% to 60% of the sera have been shown to react with PM/Scl-75 [11,12,44,45]. Raijmakers and colleagues showed that PM/Scl-75 contains a previously unidentified N-terminal region that is important for the antigenicity of the protein [ 46 ] The SCL-70 blood test is a specific test that is designed to produce specific results. Although it may not always be accurate and provide a negative result when scleroderma is present, a positive result can provide a diagnosis of this connective tissue disorder so that a treatment plan can begin. If you are experiencing any of the CREST.
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing Western blot analyses of patient sera positive for the anti-PM/Scl autoantibody revealed that the major autoantigen is the 110-kDa protein (PM/Scl-100), although some sera also recognized the 80-kDa protein (PM/Scl-75) [16,17]. Two cDNA clones encoding possible splicing variants of the PM/Scl-100 autoantigen have been isolated and char Anti-centromere, anti-Scl-70 (topoisomerase) and anti-PM-1 (Pm-Scl) can be positive in mixed connective tissue disease. Advertisement . Anti-Ro/SSA And La/SSB Antibodies. Commonly positive in primary Sjogren's syndrome, it's positive in 60-70% of cases. It can be positive in SLE, mixed connective tissue disease and scleroderma sometimes While this is high, we note that positive results were generally low level (10 of 11 false positive result in healthy controls were 1+ only) and 4 of the 11 were anti-PM/Scl-75 positive in isolation (rather than the anticipated PM/Scl-75 and PM/Scl-100)
Another study of 41 anti-PM/Scl-positive patients stated that muscle weakness was present in 37% initially but was ultimately confirmed in 93% of patients during follow-up (mean follow-up, 6.5±4.7 years) . Long periods from the onset to the recognition of muscle symptoms may be characteristic of anti-PM/Scl-positive patients . This new assay will be replacing anti-PM/Scl Ab  effective May 1st and is exclusively available at RDL. The presence of both anti-PM/Scl-100 and anti-PM. Anti-PM-Scl PM, DM, PSS, diff. Nucleoli, homogeneous ELISA: ANA Screen proﬁ les, anti-PM-Scl EUROLINE: ANA, myositis, systemic sclerosis proﬁ les AMA-like pattern BC HEp-2: coarse granular; liver: positive IFT: rat kidney, anti-M2 EUROPLUS ELISA: anti-M2-3E LINE: AMA , ANA liver proﬁ les IFT: Crithidia luciliae (anti-dsDNA) ELISA: anti. A small number of CD8-positive cells (G) and CD4-positive cells (not shown) were found, and moderate infiltra-tion by CD68-positive cells in the perimysium and endomysium is shown (H). 作用を持つ蛋白複合体に対する抗体で，それぞれ抗PM/Scl-75 抗体および抗PM/Scl-100.
3).2,8,9 If the ANA IFA is positive, a positive result on one of the cascade tiers may suggest the presence of a certain autoimmune disease(s) ( Figure 1 , Table 3 ) A total of 386 patients have been tested for specific NA over the study period. 123 patients were positive for one or more antibody/ies against/to NA, including 24 patients who were positive for several antigens simultaneously. 48 patients were positive for CENP-A/B, 38 for Ro52/TRIM21, 13 for Scl-70, 7 for RNAP-III, 3 for PM/Scl-100, 4 for PM. CLINICAL ASSOCIATIONS. Mitogen's Interstitial Lung Disease (ILD) Antibody Profile is an autoimmune diagnostic test that detects antibodies directed to Jo-1 (histidyl t-RNA synthetase) and other synthetase targets (PL7, PL-12, OJ, EJ); as well as Ku, Scl-70- (topoisomerase I), CENP-B, Scl-34 (fibrillarin), Th/To, RNA polymerase, U1-RNP, Ro52/TRIM21, Mi-2, MDA-5
Interpretation for: Anti-Jo-1 Ab, Anti-TIF-1gamma Ab, Anti-MDA-5-Ab (CADM-140), Anti-NXP-2 (P140) Ab, Anti-PM/Scl-100 Ab, Anti-SS-A 52kD Ab IgG, Anti-U1-RNP Ab: Reference Range: <20. Negative: <20 units. Weak Positive: 20-39 units. Moderate Positive: 40-80 units. Strong Positive: >80 units Policy and Procedures Checklist. Regulations (SCL) 907 KAR 12:010 & (MPW) 907 KAR 1:835. CONTENT OF SCL REGULATION SECTIONS. Definitions 10- Participant-Directed Services (PDS) Participant Eligibility, Enrollment and Termination 11- Incident Reporting Process 3- Non-PDS Provider Participation Requirements (this section also applies to Michelle P waiver) 12- SCL Waiting List 4 - SCL Services 13. The SCL-63 measures symptoms relating to psychiatric condi- As the PM and IC scales showed non-normal distribution, we. based on an initial positive screening for depression on the EPDS. Looking For Great Deals On Ibanez Pm 100? From Everything To The Very Thing. All On eBay. Get Ibanez Pm 100 With Fast And Free Shipping For Many Items On eBay
If you would like to schedule an appointment with one of our nationally ranked specialists or Primary Care physicians please click or call 800-881-7385 To confirm the presence of true-positive anti-PM/Scl and exclude false-positives, we performed 2 ELISA using different antigens, i.e., a human recombinant PM/Scl-100 protein and the PM1-α antigen. All 9 patients with anti-PM/Scl autoantibodies were positive in both assays, including the 3 patients without nucleolar fluorescence on ANA Anti-Sjögren's syndrome type A (SSA) and anti-Sjögren's syndrome type B (SSB) antibodies were raised and antibodies against PM/Scl-75 and PM/Scl-100 were strongly positive on immunofluorescence. Autoantibodies to rheumatoid factor (30 U/mL; normal <14) and anti-cyclic citrullinated peptide antibodies (19 U/mL; normal <5) were positive antibodies were raised and antibodies against PM/Scl-75 and PM/Scl-100 were strongly positive on immuno-fluorescence. Autoantibodies to rheumatoid factor (30 U/mL; normal <14) and anti-cyclic citrullinated peptide antibodies (19 U/mL; normal <5) were positive. An x-ray of the patient's pelvis showed generalise
Anti PM-Scl 100 Anti PM-Scl 75 Anti JO1 Anti SRP Anti PL-7 Anti PL-12 Anti EJ Anti OJ Anti Ro-52: Laboratory: Clinical Immunology: Specimen Type: Adult: 5 mL Gold top Vacutainer tube or 6 mL Red top Vacutainer tube as well as EDTA, heparin or citrate plasma Pediatric: 0-2 years: Red 0.5 pk 2-10 years: 2 mL Red top: Collection Information A teszt a humán szérumban vagy plazmában lévő nukleoszóma, dsDNA, hiszton, SmD1, PCNA, riboszomális P0, SSA (Ro60kD), SSA (Ro52kD), SSB (La), CENP-B, Scl-70, U1-snRNP , AMA-M2, Jo1, PM-Scl, Mi-2, Ku antigének elleni IgG antitesteket mutatja ki. Az antitestek kimutatása segítséget ad az SLE, Sjögren szindróma, CREST-szindróma, Scleroderma, MCTD, PBC és Myositis valamint más.
Exosome component 10 (EXOSC10), also named autoantigen PM/Scl-2, is the 100 kDa antigen component of PM-Scl and is recognized by most sera of PM-Scl patients. EXOSC10 is strongly enriched in the nucleolus and a small amount has been found in cytoplasm supporting the existence of a nucleolar RNA exosome complex form PM/Scl 100 fused to a hexa-histidine purification tag. Internal initiation site inactivated by point mutation of a single amino acid residue. Biochemical tests: SDS-PAGE (purity > 70%); Western blot with i: anti PM/Scl 100 autoantibody-positive sample; ii: monoclonal anti-His-tag antibody. Calculated molecular weight: 102 kDa Calculated. PM/Scl 100 fused to a hexa- histidine purification tag. Internal initiation site inactivated by point mutation of a single amino acid residue. Biochemical tests: SDS-PAGE (purity > 70%); Western blot with i: anti PM/Scl 100 autoantibody-positive sample; ii: monoclonal anti-His-tag antibody. Calculated molecular weight: 102 kD The MAAs included antibodies against PM-Scl 75, PM-Scl 100, Ku, Ro52 and U1-RNP. Sera were taken within 1 month of the MRI performance. The anti-U1-RNP antibodies were measured with a commercially available chemiluminescent enzyme immunoassay kit (STACIA MEBLux test RNP; Medical & Biological Laboratories, Nagoya, Japan) Those SLE patients positive by clinical laboratory methods also demonstrated elevated MFI in the Autoimmune Anti-PM/Scl-100. E PM GP hy. 0 500 1000 1500. MFI. Anti-Scl-70. E PM GP hy. 0 5000 10000 15000 20000. MFI. Anti-Ribosomal P. E PM GP hy. 0 5000 10000 15000 20000. MFI. Anti-PCNA. E PM GP hy. 0 500 1000 1500 200
1 Reply. The ANA test is just one blood test to help make a diagnosis. As you can see, it notes that a positive ANA is seen in healthy people. If you are concerned about a diagnosis of systemic lupus erythematosus, your first priority is to get to see a lupus specialist, as not all rheumatologists are expert in SLE Clinical details, including positive autoantibody levels, are presented in Table 1, and occupational histories are presented below to illustrate typical exposures. Table 1. Myositis antibody panel—PM-SCL 75 + PM-SCL 100: RhF: Pulmonary function test results, n (%). contain anti-PM-Scl byimmunodiffusion andto react with both the 100- and70-kD proteinsbyimmunoblotting, was usedfor screening, diluted 1/500 in 0.05 MTrisbuffer at pH 8.0 with0.15 MNaCl an Scleromyositis, is an autoimmune disease (a disease in which the immune system attacks the body). People with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is therefore considered an overlap syndrome.Although it is a rare disease, it is one of the more common overlap syndromes seen in scleroderma patients, together with MCTD and. No major differences were detected between patients positive for both anti-PM/Scl-75 and anti-PM/Scl-100 and those positive for just one. The nucleolar ANA pattern was effective as a screening technique (sensitivity=94%, specificity=92%) to detect anti-PM/Scl autoantibodies in myositis patients
Interpretation for: Anti-Jo-1 Ab, Anti-TIF-1gamma-Ab, Anti-MDA-5-Ab (CADM-140), Anti-NXP-2 (P140) Ab, Anti-SAE1 Ab IgG, Anti-PM/Scl-100 Ab, Anti-SS-A 52kD Ab IgG, Anti-U1-RNP Ab: Reference Range: <20. Negative: <20 units. Weak Positive: 20 - 39 units. Moderate Positive: 40 - 80 units - Ro-52 (1 false positive, 1 false negative) - TIF1-g(1 false negative) • Immco Diagnostics had one discordant value (OJ, false negative) • While Quest and RDL had 100% concordance they did not test for all antibodies - Did not test for: Ro-52, TIF1-g, PM-Scl, SAE1, NXP-2, MDA- Myositis Immunoblot. The Myositis immunoblot is used after specific ANA patterns are detected on immunofluorescence, when there is no agreement with ENA ELISA results, and upon specific request. The immuno blot detects IgG antibodies to cN-1A (inclusion body Myositis), MDA-5, Tif1-gamma, NXP-2, SAE-1, Mi-2a, Mi-2b, Ku, PM-Scl 100, PM-Scl-75, Jo. Anti-PM/Scl autoantibodies have been reported to occur in sera of patients with myositis (5-8%), myositis-systemic sclerosis overlap (24-50%), and systemic sclerosis (2-3%).3, 44PM/Scl-100 and PM/Scl-75 are recognised by ∼98% and ∼63% of the PM/Scl positive sera, respectively.45-4 Anti-PM/Scl and anti-Ku positive PDM/SSc are preferen- Patients seronegative by line blot testing should be evalu- tially associated with the limited cutaneous variant of SSc ated by in-house speculative testing. [20, 22], presenting less digital ulcers and much more At present, new antibody specificities are accurately myositis, arthritis and.
EXOSC10 is a nucleolar protein and represents one crucial component of the so-called PM/Scl complex or nuclear exosome, which is an RNA-processing complex consisting of a number of exoribonucleases (not to be confused with certain multivesicular bodies which are shed by cultured cells into the culture fluid and are also called exosomes).Autoantibodies against EXOSC10 occur in patients. Exosome component 10 (EXOSC10), also named autoantigen PM/Scl 2, is the 100 kDa antigen component of PM-Scl and is recognized by most sera of PM-Scl paitents. EXOSC10 is strongly enriched in the nucleolus and a small amount has been found in cytoplasm supporting the existence of a nucleolar RNA exosome complex form PM or DM (with rash) or overlap myositis See text and Table 1 . MSA Negative . Myositis Specific 11 Antibodies Panel (test code 94777) MSA Positive . Positive . Myositis Associated Antibody Tests: Ku Autoantibodies (test code 18855) Anti-PM/Scl-100 Antibody, EIA (test code 94646) Sjögren's Antibody (SS -A) (test code 38568 Different autoantibody specificities are associated with different types of SSc. Antibodies against Scl-70, RP155 and RP11 are characteristic for the diffuse form, while antibodies against CENP A, CENP B and Th/To occur in the limited form. Antibodies against Ku, PM-Scl75 and PM-Scl100 are indicative of an overlap syndrome
2. Batch-to-batch comparability, means less testing for you, saving you time and money and a quicker route to market. 3. Our Jo-1 HumAb IgG has been shown to work equally well at low dilutions when compared to anti-Jo-1 positive patient samples, so you can be satisfied that it works as effectively as characterised disease state plasma. 4 The exosome is a complex of 3′ → 5′ exoribonucleases that functions in a variety of cellular processes, all concerning the processing or degradation of RNA. Paradoxically, the previously described cDNA for the human autoantigenic exosome subunit PM/Scl-75 (Alderuccio, F., Chan, E. K., and Tan, E. M. (1991) J. Exp. Med. 173, 941-952) encodes a polypeptide that failed to interact with. (B) Transbronchial biopsies in a 58-year-old man (patient #13, ANA 1:100, positive for Scl-70; see Figure 3D for imaging) show alveolar fibromyxoid plugs with entrapment of fibrin (Bx, left; arrowhead). Other areas from the same sample show parenchymal collapse with granulation tissue around residual fibrin (yellow circle) Anti-Jo-1 Ab, Anti-TIF-1gamma Ab, Anti-MDA-5-Ab (CADM-140), Anti-NXP-2 (P140) Ab, Anti-SAE1 Ab IgG, Anti-PM/Scl-100 Ab, Anti-SS-A 52kD Ab IgG, Anti-U1-RNP Ab: Reference Range: <20. Negative: <20 units. Weak Positive: 20-39 units. Moderate Positive: 40-80 units. Strong Positive:>80 units Rheumatologic Testing in Pr imary Care October 4, 2008 Fernando Vega, M.D. 2 Anti-Nuclear Antibodies zCurrently we use the Fluorescent Antinuclear Antibody Test (FANA) zAntibodies attach to ppprepared cells from the lab zSerum is washed off with antibodies left behind zAntibodies are stained with fluorescent Ab zResults are observed manually by microscop